A drug that combines the muscarinic receptor agonist xanomeline and the muscarinic receptor antagonist trospium reduced positive and negative symptoms of schizophrenia in a Phase 3 placebo-controlled trial. The study's investigators wrote that the results suggest the drug, known as KarXT, could represent a new class of antipsychotic medications. Results were published online Dec. 14, 2023, in The Lancet.
A retrospective cohort study involving Medicaid-insured children and young adults receiving second-generation antipsychotics has found an increased risk of mortality only in the young-adult group that received high doses of the medication. There was no association between antipsychotic use and increased mortality risk for children aged 5 to 17 or for young adults aged 18 to 24 taking lower doses of antipsychotics.
Escitalopram (generic) – Lexapro (brand)
Longer duration of medication use for attention-deficit hyperactivity disorder (ADHD) was associated with an increased risk of hypertension and arterial disease, a case-control study has found. Over a 14-year period, risk of cardiovascular diseases had the steepest increases during the first 3 years of cumulative use, the investigators reported. Study results were published online Nov. 22, 2023, in JAMA Psychiatry.
In addition to its approved use for the treatment of patients with attention-deficit hyperactivity disorder (ADHD), the selective norepinephrine reuptake inhibitor atomoxetine is sometimes used off-label as an adjunctive therapy for patients with major depressive disorder. Bupropion, a norepinephrine/dopamine reuptake inhibitor approved for the treatment of depression, is also used off-label for ADHD. Bupropion is a potent inhibitor of CYP2D6, the cytochrome P-450 isoenzyme responsible for mediating the primary hydroxylation pathway of atomoxetine to its active metabolite 4-hydroxy-atomoxetine.
Two Phase 3 placebo-controlled trials of the anti-amyloid monoclonal antibody gantenerumab failed to result in a slowing of clinical decline in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. Use of gantenerumab did result in a reduction in brain amyloid plaque levels. Results of the trials were published Nov. 16, 2023, in the New England Journal of Medicine.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：